A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Amounts are shown in US dollars, translated from CNY at the rate recorded for each period. Growth rates marked (CNY) are measured in CNY, the currency the company reports in, so a move in the exchange rate does not count as growth.
Newest figures come from the 20-F for FY2025, filed Apr 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NCTY SEC filings page.
The9 Limited (NCTY) reported $15.4M in revenue for fiscal year 2025, down 3.4% in CNY terms from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
Near-flat revenue now produces a much larger loss because overhead expanded faster than the small gross-profit recovery.
The business achieved a small gross-margin recovery in FY2025, but operating margin fell207.9 percentage points . SG&A climbed from$21.7M to$34.3M while sales were nearly unchanged, showing that overhead—not direct production cost—now dominates the operating result.
Accounting earnings and cash generation disagree: FY2023 reported net income of
Financing is carrying the funding burden: financing cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of The9 Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
The9 Limited held $32.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $4.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and The9 Limited scores 77/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. The9 Limited scores 16/100 on it among other emerging companies.
The9 Limited spent $1.4M on research and development in fiscal year 2025, which was 2.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and The9 Limited scores 15/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. The9 Limited scores 18/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. The9 Limited scores 65/100 on it among other emerging companies.
The9 Limited's cash, cash equivalents and investments came to $32.9M at the end of fiscal year 2025, against $50.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and The9 Limited scores 49/100 among other emerging companies.
The9 Limited scores -12.24, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $691.1M against total assets of $84.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
The9 Limited passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
The9 Limited reported a net loss of $57.5M while operations used $4.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
The9 Limited reported an operating loss of $40.2M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
The9 Limited generated $15.4M in revenue in fiscal year 2025. This represents a decrease of 3.4% in CNY terms from the prior year.
The9 Limited reported a net loss of $57.5M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
The9 Limited earned -$0.03 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Cash & Balance Sheet
The9 Limited held $8.4M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
The9 Limited's gross margin was 1.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the prior year.
The9 Limited's ROE was -210.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 189.2 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
The9 Limited invested $1.4M in research and development in fiscal year 2025. This represents an increase of 1044.6% in CNY terms from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
NCTY Income Statement
Figures in USD, translated from CNY at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F | FY1320-F | FY1220-F | FY1120-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.4M-3.4% | $15.3M-35.8% | $24.5M+65.9% | $15.2M-22.6% | $21.3M+21575.3% | $96K+83.2% | $49K-98.0% | $2.5M-76.1% | $11.3M+30.1% | $8.1M+20.8% | $7.2M-28.1% | $10.5M-39.2% | $17.6M-34.8% | $26.3M+45.4% | $17.9M |
| Cost of Revenue | $15.2M-6.4% | $15.5M-46.8% | $30.0M+40.0% | $22.1M+73.5% | $13.8M+10684.6% | $125K-39.3% | $193K-91.8% | $2.4M-30.9% | $3.7M-51.0% | $7.0M-28.4% | $10.5M-21.0% | $13.8M-20.4% | $17.8M+55.3% | $11.1M+77.5% | $6.2M |
| Gross Profit | $259Kn/m | -$220Kn/m | -$5.5Mn/m | -$6.9M-199.2% | $7.5Mn/m | -$29Kn/m | -$144K-200.5% | $145K-98.0% | $7.6M+542.8% | $1.1Mn/m | -$3.3Mn/m | -$3.5Mn/m | -$500K-103.6% | $13.6M+26.4% | $10.7M |
| R&D Expenses | $1.4M+1044.6% | $117K-56.5% | $277K-19.0% | $353K+26.9% | $301K-21.3% | $374K-81.4% | $1.9M-46.7% | $3.6M-45.6% | $6.9M-42.2% | $11.2M-42.2% | $20.8M-13.6% | $25.2M-26.7% | $35.2M-29.3% | $48.4M+42.1% | $33.7M |
| SG&A Expenses | $34.3M+51.7% | $21.7M-20.4% | $28.0M-45.4% | $52.7M+24.9% | $45.7M+166.0% | $16.8M-5.7% | $16.7M+26.2% | $13.4M-22.1% | $18.1M-21.6% | $21.7M-8.0% | $25.2M+0.3% | $26.3M-41.5% | $46.0M-22.0% | $57.4M+34.8% | $42.1M |
| Operating Income | -$40.2Mn/m | -$8.1Mn/m | -$44.8Mn/m | -$95.9Mn/m | -$48.3M-191.4% | $51.6Mn/m | -$23.5Mn/m | -$15.2Mn/m | -$17.4Mn/m | -$42.6Mn/m | -$50.4Mn/m | -$25.9Mn/m | -$87.6Mn/m | -$95.1Mn/m | -$61.0M |
| EBITDA | N/A | N/A | -$32.5Mn/m | -$82.7Mn/m | -$40.8M | N/A | N/A | -$14.7Mn/m | -$16.6Mn/m | -$41.5Mn/m | -$48.6Mn/m | -$23.4Mn/m | -$84.4M | N/A | N/A |
| Interest Expense | $3.3M-32.0% | $4.7M+9.1% | $4.4M+34.5% | $3.4M-80.4% | $18.7M+2828.0% | $624K-88.2% | $5.0M-67.1% | $15.2M+24.8% | $12.9M+48.6% | $8.1M+782.8% | $988K | N/A | N/A | N/A | N/A |
| Income Tax | $16Kn/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $1.1Mn/m | $0n/m | $0n/m | $0n/m | -$876Kn/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $26 |
| Net Income | -$57.5Mn/m | -$10.1M-467.1% | $2.8Mn/m | -$141.3Mn/m | -$64.5M-203.4% | $61.0Mn/m | -$25.5Mn/m | -$31.6Mn/m | -$18.2Mn/m | -$85.5Mn/m | -$59.4Mn/m | -$17.4Mn/m | -$86.9Mn/m | -$82.5Mn/m | -$45.2M |
| EPS (Basic) | -$0.03n/m | -$0.01 | $0.00n/m | -$0.20n/m | -$0.13 | $0.37 | -$0.26 | -$0.60 | -$0.81n/m | -$4.08n/m | -$2.55n/m | -$0.75n/m | -$3.75n/m | -$3.37n/m | -$1.81 |
| EPS (Diluted) | -$0.03n/m | -$0.01 | $0.00n/m | -$0.20n/m | -$0.13 | $0.37 | -$0.26 | -$0.60 | -$0.81n/m | -$4.08n/m | -$2.55n/m | -$0.75n/m | -$3.75n/m | -$3.37n/m | -$1.81 |
| Diluted Shares (Avg) | 2.27B+62.0% | 1.40B | 1.01B+40.4% | 720M+45.4% | 495M | 164M | 106M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NCTY Balance Sheet
Figures in USD, translated from CNY at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F | FY1320-F | FY1220-F | FY1120-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $84.9M-6.7% | $87.2M+75.0% | $51.2M-39.3% | $86.9M-54.3% | $205.6M+2605.0% | $7.4M-73.3% | $26.1M+10.2% | $24.0M-49.0% | $49.7M-7.9% | $50.5M-34.8% | $83.1M+4.0% | $83.4M-5.4% | $90.3M-50.9% | $178.5M-31.7% | $258.8M |
| Current Assets | $49.0M+40.5% | $33.4M+35.1% | $25.4M-54.2% | $57.0M-62.5% | $164.8M+2382.6% | $6.5M-72.6% | $22.2M+367.9% | $4.8M-82.0% | $28.1M+108.0% | $12.7M+14.0% | $11.9M-69.8% | $41.2M+17.3% | $36.0M-67.2% | $106.7M-43.1% | $185.7M |
| Cash & Equivalents | $8.4M+436.1% | $1.5M-75.9% | $6.4M-22.1% | $8.4M-86.4% | $67.2M+1251.6% | $4.9M+213.4% | $1.5M+137.6% | $619K-97.0% | $21.9M+266.8% | $5.6M-20.7% | $7.6M-73.0% | $29.2M+15.6% | $25.9M-71.7% | $89.0M-48.3% | $170.3M |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0-100.0% | $126Kn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $141Kn/m | $0 |
| Accounts Receivable | N/A | N/A | $8K-63.0% | $22K-95.9% | $578K+123425.1% | $457-97.3% | $16K-81.4% | $86K-77.3% | $401K-69.7% | $1.2M+20.3% | $1.1M-39.4% | $1.9M-38.3% | $3.2M+22.5% | $2.5M+55.4% | $1.6M |
| Long-Term Investments | $24.5M-42.3% | $40.7Mn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $1.0M-0.9% | $1.0M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m | $0n/m | $0-100.0% | $1.6M+6.1% | $1.6M+0.4% | $1.6M-3.0% | $1.6M-0.2% | $1.6M |
| Total Liabilities | $50.2M+67.9% | $28.7M+14.7% | $25.7M-68.1% | $82.9M+4.5% | $85.8M+49.1% | $56.2M-65.5% | $152.9M+17.2% | $132.1M+10.9% | $125.9M+18.7% | $99.5M-6.1% | $113.5M+129.2% | $51.7M-10.0% | $58.9M-1.8% | $58.3M-3.7% | $59.9M |
| Current Liabilities | $49.1M+67.0% | $28.2M+26.3% | $22.9M-71.1% | $81.8M+3.7% | $85.4M+49.4% | $55.8M-65.6% | $152.0M+16.5% | $132.1M+10.9% | $125.9M+42.8% | $82.6M+34.1% | $66.1M+44.3% | $47.8M-10.1% | $54.5M+3.9% | $51.0M+2.0% | $49.5M |
| Non-Current Liabilities | $1.1M+121.6% | $483K-81.9% | $2.8M+163.8% | $1.1M+188.5% | $403K+4.2% | $378K-60.6% | $898Kn/m | $0n/m | $0-100.0% | $16.8M-62.0% | $47.5M+1162.6% | $3.9M-7.9% | $4.4M-41.8% | $7.3M-30.7% | $10.4M |
| Long-Term Debt | N/A | N/A | $2.4M | N/A | N/A | N/A | N/A | N/A | N/A | $28.4M+45.9% | $20.9M | N/A | N/A | N/A | N/A |
| Total Equity | $27.3M-43.6% | $46.4M+64.2% | $29.1M+355.3% | $6.6M-94.2% | $121.8Mn/m | -$44.1Mn/m | -$120.5Mn/m | -$103.5Mn/m | -$72.8Mn/m | -$48.9Mn/m | -$30.5M-301.3% | $15.8M-62.4% | $43.1M-66.8% | $126.1M-37.8% | $200.6M |
| Retained Earnings | -$691.1Mn/m | -$606.9Mn/m | -$613.6Mn/m | -$634.8Mn/m | -$534.1Mn/m | -$458.6Mn/m | -$489.9Mn/m | -$470.2Mn/m | -$463.5Mn/m | -$417.4Mn/m | -$355.7Mn/m | -$322.2Mn/m | -$315.9Mn/m | -$222.5Mn/m | -$138.6M |
Not reported in any period shown, so not listed: Inventory.
NCTY Cash Flow Statement
Figures in USD, translated from CNY at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F | FY1320-F | FY1220-F | FY1120-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.5Mn/m | -$6.1Mn/m | -$6.5Mn/m | -$22.3Mn/m | -$110.5Mn/m | -$16.3Mn/m | -$7.8Mn/m | -$14.7Mn/m | -$13.3Mn/m | -$25.9Mn/m | -$27.1M-165.2% | $43.4Mn/m | -$59.1Mn/m | -$78.5Mn/m | -$43.0M |
| Depreciation & Amortization | N/A | N/A | $12.2M-4.9% | $13.2M+92.6% | $7.4M | N/A | N/A | $531K-31.1% | $814K-27.6% | $1.1M-36.7% | $1.8M-26.2% | $2.5M-17.7% | $3.1M | N/A | N/A |
| Stock-Based Compensation | $16.6M+159.8% | $6.1M-36.9% | $10.0M-65.0% | $29.3M+34.7% | $23.6M+172.8% | $8.4M+153.1% | $3.1M+457.9% | $567K-89.7% | $5.8M+35.6% | $4.0M-17.5% | $5.2M+826.1% | $592K-87.4% | $4.8M-21.8% | $6.0M-29.8% | $8.5M |
| Investing Cash Flow | $159Kn/m | -$7.8M-1375.6% | $630Kn/m | -$36.2Mn/m | -$19.7M-128.6% | $67.2M+619.9% | $8.7Mn/m | -$2.5M-110.7% | $24.9Mn/m | -$1.4M | N/A | N/A | -$484Kn/m | -$3.6Mn/m | -$6.6M |
| Financing Cash Flow | $11.2M+12.5% | $9.6M+114.9% | $4.6M-1.8% | $4.8M-97.3% | $192.6Mn/m | -$47.6M-859.2% | $5.9Mn/m | -$2.7M-141.7% | $6.8M-76.8% | $27.4M | N/A | N/A | -$6.4Mn/m | -$1.1Mn/m | -$3.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $4.8M+3357.9% | $135K-96.0% | $3.4M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow.
NCTY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F | FY1320-F | FY1220-F | FY1120-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 1.7%+3.1pp | -1.4%+21.0pp | -22.5%+22.7pp | -45.1%-80.4pp | 35.2%+65.4pp | -30.2% | -293.1% | 5.7%-61.7pp | 67.4%+53.8pp | 13.7%+59.4pp | -45.8%-12.6pp | -33.2%-30.3pp | -2.8%-54.8pp | 52.0%-7.8pp | 59.8% |
| Operating Margin | -260.5% | -52.6% | -182.6% | -630.5% | -226.9% | 53831.3% | -47941.2% | -598.9% | -154.8% | -525.2% | -700.5% | -248.1% | -497.3% | -362.1% | -341.5% |
| Net Margin | -373.0% | -65.7%-77.2pp | 11.5% | -929.1% | -303.3% | 63611.7% | -52063.8% | -1241.1% | -161.4% | -1054.9% | -825.2% | -166.1% | -493.6% | -314.2% | -252.8% |
| Return on Equity | -210.8%-189.2pp | -21.7%-31.4pp | 9.7%+2161.3pp | -2151.6%-2098.6pp | -53.0% | N/A | N/A | N/A | N/A | N/A | N/A | -109.9%+92.0pp | -201.8%-136.4pp | -65.4%-42.9pp | -22.5% |
| Return on Assets | -67.8%-56.3pp | -11.5%-17.0pp | 5.5%+168.2pp | -162.7%-131.3pp | -31.4%-852.8pp | 821.4%+919.4pp | -98.0%+33.8pp | -131.8%-95.3pp | -36.6%+132.6pp | -169.2%-97.7pp | -71.5%-50.7pp | -20.8%+75.4pp | -96.3%-50.1pp | -46.2%-28.7pp | -17.5% |
| Current Ratio | 1.00-0.2x | 1.19+0.1x | 1.11+0.4x | 0.70-1.2x | 1.93+1.8x | 0.120.0x | 0.15+0.1x | 0.04-0.2x | 0.22+0.1x | 0.150.0x | 0.18-0.7x | 0.86+0.2x | 0.66-1.4x | 2.09-1.7x | 3.75 |
| Debt-to-Equity | N/A | N/A | 0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 1.84+1.2x | 0.62-0.3x | 0.88-11.7x | 12.61+11.9x | 0.70 | N/A | N/A | N/A | N/A | N/A | N/A | 3.27+1.9x | 1.37+0.9x | 0.46+0.2x | 0.30 |
| Asset Turnover | 0.180.0x | 0.18-0.3x | 0.48+0.3x | 0.18+0.1x | 0.10+0.1x | 0.010.0x | 0.00-0.1x | 0.11-0.1x | 0.23+0.1x | 0.16+0.1x | 0.090.0x | 0.13-0.1x | 0.200.0x | 0.15+0.1x | 0.07 |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (1.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| The9 Limited NCTY | FY2025 | $15.4M | -$57.5M | N/A | $44.6M | 40/100 |
| Metalpha Technology Holding Limited MATH | FY2026 | $37.1M | $1.3M | 3.5% | $41.7M | 56/100 |
| BTCS Inc. BTCS | FY2025 | $16.5M | -$33.4M | N/A | $39.4M | 27/100 |
| Aurelion Inc. AURE | FY2025 | N/A | N/A | N/A | $38.7M | — |
| Streamex Corp. STEX | FY2025 | N/A | -$462.8M | N/A | $35.5M | — |
| Heritage Global Inc HGBL | FY2025 | $51.0M | $3.6M | 7.0% | $36.0M | 57/100 |
Where The9 Limited Ranks
Frequently Asked Questions
The9 Limited (NCTY) reported $15.4M in total revenue for fiscal year 2025. This represents a -3.4% change in CNY terms compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
The9 Limited (NCTY) revenue declined by 3.4% year-over-year in CNY, the currency it reports in. Translated at each year’s own exchange rate, it went from $15.3M to $15.4M in fiscal year 2025.
No, The9 Limited (NCTY) reported a net loss of $57.5M in fiscal year 2025.
The9 Limited (NCTY) had a gross margin of 1.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
The9 Limited (NCTY) has a return on equity of -210.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
The9 Limited (NCTY) recorded an outflow of $4.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
The9 Limited (NCTY) had $84.9M in total assets as of fiscal year 2025, including both current and long-term assets.
The9 Limited (NCTY) invested $1.4M in research and development during fiscal year 2025.
The9 Limited (NCTY) had a current ratio of 1.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
The9 Limited (NCTY) had a liabilities-to-equity ratio of 1.84 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
The9 Limited (NCTY) had a return on assets of -67.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
The9 Limited (NCTY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $44.6M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
The9 Limited (NCTY) trades at 2.9x sales, its market capitalization divided by $15.4M revenue, FY2025. The market capitalization is $44.6M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
The9 Limited (NCTY) has an Altman Z-Score of -12.24, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
The9 Limited (NCTY) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
The9 Limited (NCTY) reported a net loss of $57.5M while operations used $4.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
The9 Limited (NCTY) reported an operating loss of $40.2M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
The9 Limited (NCTY) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.